Actinic keratoses - a systemic review

Cover Page


Cite item

Full Text

Abstract

Mainly elderly people with pale skin are affected by actinic keratoses (AK). Due to the demographic change, the prevalence of AK increased over the last years. An established risk factor is chronic UV-exposure (outdoor workers) inducing mutations of the tumor suppressor gene TP53 and the oncogene H-Ras. This leads to an intraepidermal proliferation of atypical keratinocytes. The term “field cancerization” characterises the presentation of multiple AK in UV-exposed areas. AK are also termed squamous cell carcinoma (SCC) in situ. The risk for AK turning into a SCC is 6-10%. In order to avoid invasive growth, an early treatment is recommended. During the last years multiple therapeutic options have been established. Depending on the clinical extent, lesion- or field-directed therapies with excellent clinical response and cosmetic results are available.

About the authors

T. . Strunk

Academic Teaching Hospital

Author for correspondence.
Email: Strunk@klinikum-vest.de
Россия

L. R. Braathen

Dermatology Bern

Email: noemail@neicon.ru
Россия

R. -M. Szeimies

Academic Teaching Hospital

Email: noemail@neicon.ru
Россия

References

  1. Pinkus H. Keratosis senilis: a biologic concept of its pathogenesis and diagnosis based on the study of normal epidermis and 1730 seborrheic and senile keratoses. Am J Clin Pathol 1958; 29: 193-207.
  2. Memon A.A., Tomenson J.A., Bothwell J. et al. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000; 142: 1154-9.
  3. Schaefer I., Augustin M., Spehr C. et al. Prevalence and risk factors of actinic keratoses in Germany - analysis of multisource data. J Eur Acad Dermatol Venereol 2013; 28: 309-13.
  4. Traianou A., Ulrich M., Apalla Z. et al. Risk factors for actinic keratosis in eight European centers: a case-control study. Br J Dermatol 2012; 167(Suppl 2): 36-42.
  5. Hensen P., Müller M.L., Haschemi R. et al. Predisposing factors of actinic keratosis in a NorthWest German population. Eur J Dermatol 2009; 19: 345-54.
  6. Oldenburg M., Kuechmeister B., Ohnemus U. et al. Actinic keratosis among seafarers. Arch Dermatol Res 2013; 305: 787-96.
  7. Schmitt J., Seidler A., Diepgen T.L. et al. Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol 2011; 164: 291-307.
  8. Ulrich C., Schmook T., Nindl I. et al. Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. Br J Dermatol 2003; 149(Suppl 2): 40-2.
  9. Babilas P., Landthaler M., Szeimies R.M. Actinic keratoses. Hautarzt 2003; 54: 551-62.
  10. Luo J.L., Tong W.M., Yoon J.H. et al. UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot e.g. in sun-exposed human skin. Cancer Res 2001; 61: 8158-63.
  11. Tomas D. Apoptosis, UV-radiation, precancer-osis and skin tumor. Acta Med Croatica 2009; 63(Suppl 2): 53-8.
  12. Pierceall W.E., Goldberg L.H., Tainsky M.A. et al. Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog 1991; 4: 196-202.
  13. Ratushny V., Gober M.D., Hick R. et al. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 2012; 122: 464-72.
  14. Lacouture M.E., Duvic M., Hauschild A. et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013; 18: 314-22.
  15. Zaravinos A., Kanellou P., Spandidos D.A. Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers. Br J Dermatol 2009; 162: 325-31.
  16. Weissenborn S.J., Nindl I., Purdie K. et al. Human Papilloma Virus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol 2005; 125: 93-7.
  17. Pfister H. HPV and skin dose. Hautarzt 2008; 59: 26-30.
  18. Nashan D., Meiss F., Muller M. Therapeutic strategies for actinic keratoses-a systematic review. Eur J Dermatol 2013; 23: 14-32.
  19. Branzan A.L., Landthaler M., Szeimies R.M. In vivo confocal scanning laser microscopy in dermatology. Lasers Med Sci 2007; 22: 73-82.
  20. Röwert-Huber J., Patel M.J., Forschner T. et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156 (Suppl 3): 8-12.
  21. Cockerell C.J. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis”). J Am Acad Dermatol 2000; 42(1 Pt 2): 11-7.
  22. Cockerell C.J. Pathology and pathobiology of the actinic (solar) keratosis. Br J Dermatol 2003; 149 (Suppl 66):The code 34-6.
  23. Ramos-Ceballos F.I., Ounpraseuth S.T., Horn T.D. Diagnostic concordance among dermatopatholo-gists using a three-tiered keratinocytic intraepithelial neoplasia grading scheme. J Cutan Pathol 2008; 35: 386-91.
  24. Werner R.N., Sammain A., Erdmann R. et al. The natural history of actinic keratosis: a systematic review. Br J Dermatol 2013; 169: 502-18.
  25. Marks R., Foley P., Goodman G. et al. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986; 115: 649-55.
  26. Dodson J.M., DeSpain J., Hewett J.E. et al. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol 1991; 127: 1029-31.
  27. Fuchs A., Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg 2007; 33: 1099-101.
  28. Braathen L.R., Morton C.A., Basset-Seguin N. et al. Photodynamic therapy for skin field cancer-ization: an international consensus. International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol 2012; 26: 1063-6.
  29. Ulrich C., Jürgensen J.S., Degen A. et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161 (Suppl 3): 78-84.
  30. Patel G., Armstrong A.W., Eisen D.B. Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratoses: A systematic review and metaanalysis. JAMA Dermatol doi: 10.1001/jamadermatol. 2014.1253. [Epub ahead of print].
  31. Andrews M.D. Cryosurgery for common skin conditions. Am Fam Physician 2004; 69: 2365-72.
  32. Thai K.E., Fergin P., Freeman M. A prospective study of the use of Cryosurgery for the treatment of actinic keratoses. Int J Dermatol 2004; 43: 687-92.
  33. Kaufmann R., Spelman L., Weightman W. et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol 2008; 158: 994-9.
  34. Szeimies R.M., Karrer S., Radakovic-Fijan S. et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47: 258-262.
  35. Wollina U., Konrad H., Karamfilov T. Treatment of common queue and actinic keratoses by Er:YAG laser. J Cutan Laser Ther 2001; 3: 63-6.
  36. Stockfleth E., Kerl H., Zwingers T. et al. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 2011; 165: 1101-8.
  37. Hauschild A., Stockfleth E., Popp G. et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol 2009; 160: 1066-74.
  38. Szeimies R.M., Stockfleth E., Popp G. et al. Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. Br J Dermatol 2010; 162: 410-4.
  39. Pflugfelder A., Welter A.K., Leiter U. et al. Open label randomized study comparing 3 months vs. 6 Months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol 2012; 26: 48-53.
  40. Iraji F., Siadat A.H., Asilian A. et al. The safety of diclofenac for the management and treatment of actinic keratoses. Expert Opin Drug Saf 2008; 7: 167-72.
  41. Alomar A., Bichel J., McRae S. vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007; 157: 133-41.
  42. Lebwohl M., Dinehart S., Whiting D. et al. Imiquimod 5% cream for the treatment of actinic keratosis: Results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50: 714-21.
  43. Korman N., Moy R., Ling M. et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallelgroup, vehicle-controlled trials. Arch Dermatol 2005; 141: 467-73.
  44. Swanson N., Abramovits W., Berman B. et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebocontrolled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010; 62: 582-90.
  45. Hanke C.W., Beer K.R., Stockfleth E. et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol 2010; 62: 573-81.
  46. Swanson N., Smith C.C., Kaur M. et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies. J Drugs Dermatol 2013; 12: 1278-82.
  47. Lebwohl M., Swanson N., Anderson L.L. et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366: 1010-9.
  48. Lebwohl M., Shumack S., Stein Gold L. et al. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol 2013; 149: 666-70.
  49. Berman B., Goldenberg G., Hanke C.W. et al. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results. J Drugs Dermatol 2014; 13: 154-60.
  50. Berman B., Goldenberg G., Hanke C.W. et al. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results. J Drugs Dermatol 2014; 13: 741-7.
  51. Jury C.S., Ramraka-Jones V.S., Gudi V. et al. A randomized trial of topical 5% 5-fluorouracil (Efudix cream) in the treatment of actinic keratoses comparing daily with weekly treatment. Br J Dermatol 2005; 153: 808-10.
  52. Loven K., Stein L., Furst K. et al. Evaluation of the efficacy and tolerability of 0.5 % fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002; 24: 990-1000.
  53. Sander C.A., Pfeiffer C., Kligman A.M. et al. Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin. J Am Acad Dermatol 1997; 36(2 Pt 1): 236-8.
  54. Szeimies R.M., Karrer S., Bäcker H. Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen’s disease, squamous cell carcinoma, and basal cell carcinoma. Hautarzt 2005; 56: 430-40.
  55. Dirschka T., Radny P., Dominicus R. et al. Longterm (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol 2013; 168: 825-36.
  56. Szeimies R.M., Torezan L., Niwa A. et al. Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol 2012; 167: 150-9.
  57. Apalla Z., Sotiriou E., Chovarda E. et al. Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol 2010; 162: 171-5.
  58. Morton C.A., Szeimies R.M., Sidoroff A. et al. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications - actinic keratoses, Bowen's disease, basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27: 536-44.
  59. Wiegell S.R., Fabricius S., Stender I.M. et al. A randomized, multicentre study of directed daylight exposure times of 1/ vs. 2% H in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br J Dermatol 2011; 164: 1083-90.
  60. Szeimies R.M., Basset-Seguin N., Rubel D. et al. Efficacy and safety of methyl aminolaevulinate cream activated by daylight in actinic keratosis: two randomized, investigator-blinded, controlled phase 3 studies in Europe and Australia. Br J Dermatol 2014; 171(Suppl. 4): 76.
  61. Togsverd-Bo K., Haak C.S., Thaysen-Petersen D. et al. Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: a randomized clinical trial. Br J Dermatol 2012; 166: 1262-9.
  62. Torezan L., Chaves Y., Niwa A. et al. A pilot split-face study comparing conventional methyl aminolevulinate-photodynamic therapy (PDT) with microneedling-assisted PDT on actinically damaged skin. Dermatol Surg 2013; 39: 1197-201.
  63. Serra-Guillén C., Nagore E., Hueso L. et al. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol 2012; 66: 131-7.
  64. Ondo A.L., Padilla R.S., Miedler J.D., Cockerell C.J. et al. Treatment-refractory actinic keratoses successfully treated using simultaneous combination topical 5-fluorouracil cream and imiquimod cream: a case-control study. Dermatol Surg 2012; 38: 1469-76.
  65. Reifenberger J., Schön M.P. Cutaneous epithelial tumor. Molecular biology and pathogenesis-based therapy. Hautarzt 2003; 54: 1164-70.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Strunk T..., Braathen L.R., Szeimies R.-.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies